Baxter/Nexell
This article was originally published in The Gray Sheet
Executive Summary
Firms ink definitive agreement for Baxter to distribute Nexell cell processing products, including the Isolex 300i magnetic cell selection system, worldwide. A letter of intent was announced in June (1"The Gray Sheet" June 18, 2001, p. 15). As part of the deal, Baxter will acquire certain assets and liabilities of the business for an estimated $4.3 mil. and will pay royalties on future sales. Closing is expected by Oct. 1
You may also be interested in...
Baxter To Resume U.S. Distribution Of Nexell Cell Processing Systems
Baxter will resume full distribution responsibilities for Nexell Therapeutic's Isolex 300i magnetic cell selection system as part of a Nexell effort to move out of the device business in favor of biological therapeutics.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.